MRSN
Income statement / Annual
Last year (2023), Mersana Therapeutics, Inc.'s total revenue was $36.86 M,
an increase of 38.65% from the previous year.
In 2023, Mersana Therapeutics, Inc.'s net income was -$171.67 M.
See Mersana Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$36.86 M
|
$26.58 M
|
$43,000.00
|
$828,000.00
|
$42.12 M
|
$10.59 M
|
$17.55 M
|
$25.17 M
|
$10.36 M
|
| Cost of Revenue |
$1.52 M |
$927,000.00 |
$132.01 M |
$67.04 M |
$55.04 M |
$59.92 M |
$928,000.00 |
$32.01 M |
$21.35 M |
| Gross Profit |
$35.34 M |
$25.65 M |
-$131.97 M |
-$66.21 M |
-$12.92 M |
-$49.32 M |
$16.62 M |
-$6.84 M |
-$10.99 M |
| Gross Profit Ratio |
0.96 |
0.97 |
-3069.07 |
-79.96 |
-0.31 |
-4.66 |
0.95 |
-0.27 |
-1.06 |
| Research and Development
Expenses |
$148.27 M
|
$173.39 M
|
$132.01 M
|
$67.04 M
|
$55.04 M
|
$59.92 M
|
$46.70 M
|
$32.01 M
|
$21.35 M
|
| General & Administrative
Expenses |
$59.54 M
|
$56.96 M
|
$36.89 M
|
$21.90 M
|
$17.28 M
|
$16.33 M
|
$10.46 M
|
$6.98 M
|
$5.35 M
|
| Selling & Marketing
Expenses |
-$1.52 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$58.03 M
|
$56.96 M
|
$36.89 M
|
$21.90 M
|
$17.28 M
|
$16.33 M
|
$10.46 M
|
$6.98 M
|
$5.35 M
|
| Other Expenses |
$8.71 M |
-$445,000.00 |
-$1.20 M |
$0.00 |
$0.00 |
$1.40 M |
$0.00 |
$0.00 |
-$89,000.00 |
| Operating Expenses |
$206.30 M |
$230.35 M |
$168.90 M |
$88.94 M |
$72.32 M |
$76.25 M |
$57.16 M |
$38.99 M |
$26.70 M |
| Cost And Expenses |
$207.81 M |
$230.35 M |
$168.90 M |
$88.94 M |
$72.32 M |
$76.25 M |
$57.16 M |
$38.99 M |
$26.70 M |
| Interest Income |
$12.07 M |
$2.88 M |
$65,000.00 |
$424,000.00 |
$2.23 M |
$1.40 M |
$910,000.00 |
$121,000.00 |
$2,000.00 |
| Interest Expense |
$4.07 M |
$3.33 M |
$1.27 M |
$359,000.00 |
$234,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.52 M
|
$927,000.00
|
$855,000.00
|
$1.01 M
|
$1.25 M
|
$1.26 M
|
$928,000.00
|
$655,000.00
|
$297,000.00
|
| EBITDA |
-$169.44 M
|
-$203.77 M
|
-$168.86 M
|
-$86.68 M
|
-$27.97 M
|
-$65.66 M
|
-$38.69 M
|
-$13.17 M
|
-$16.04 M
|
| EBITDA Ratio |
-4.6 |
-7.67 |
-3926.93 |
-104.68 |
-0.66 |
-6.2 |
-2.21 |
-0.52 |
-1.55 |
| Operating Income Ratio
|
-4.64
|
-7.7
|
-3946.81
|
-105.9
|
-0.69
|
-6.2
|
-2.26
|
-0.55
|
-1.58
|
| Total Other
Income/Expenses Net |
-$713,000.00
|
$482,000.00
|
-$347,000.00
|
-$359,000.00
|
$1.01 M
|
$1.40 M
|
$910,000.00
|
$121,000.00
|
-$89,000.00
|
| Income Before Tax |
-$171.67 M |
-$204.21 M |
-$170.06 M |
-$88.05 M |
-$28.21 M |
-$64.26 M |
-$38.71 M |
-$13.70 M |
-$16.43 M |
| Income Before Tax Ratio
|
-4.66
|
-7.68
|
-3954.88
|
-106.33
|
-0.67
|
-6.07
|
-2.21
|
-0.54
|
-1.59
|
| Income Tax Expense |
$1.35 M |
$3.33 M |
-$855,000.00 |
$359,000.00 |
-$1.01 M |
$1.40 M |
$0.00 |
$0.00 |
-$2,000.00 |
| Net Income |
-$171.67 M |
-$207.54 M |
-$169.21 M |
-$88.40 M |
-$27.20 M |
-$64.26 M |
-$38.71 M |
-$13.70 M |
-$16.43 M |
| Net Income Ratio |
-4.66 |
-7.81 |
-3935 |
-106.77 |
-0.65 |
-6.07 |
-2.21 |
-0.54 |
-1.59 |
| EPS |
-1.48 |
-2.22 |
-2.4 |
-1.44 |
-0.63 |
-2.79 |
-3.22 |
-0.78 |
-0.94 |
| EPS Diluted |
-1.48 |
-2.22 |
-2.4 |
-1.44 |
-0.63 |
-2.79 |
-3.22 |
-0.78 |
-0.94 |
| Weighted Average Shares
Out |
$116.11 M
|
$93.65 M
|
$70.58 M
|
$61.49 M
|
$43.40 M
|
$23.03 M
|
$12.02 M
|
$17.49 M
|
$17.49 M
|
| Weighted Average Shares
Out Diluted |
$116.11 M
|
$93.65 M
|
$70.58 M
|
$61.49 M
|
$43.49 M
|
$23.03 M
|
$12.02 M
|
$17.49 M
|
$17.49 M
|
| Link |
|
|
|
|
|
|
|
|
|
